Gilead Sciences, Inc. (GILD)

Gilead Sciences (GILD) share price gained nearly 3% on Friday and was set to record its best day in about three months after Federal regulators granted accelerated approval to Hepcludex, making it the first and only approved treatment in the U.S. for adul

Gilead Sciences, Inc. Q1 update: Trodelvy, Livdelzi & Yeztugo drive $701M (+110% QoQ) as cell therapy lags. Click for this GILD update.

The company reported earnings of $2.03 per share, beating estimates of $1.95 by $0.08. The company also reported revenue of $6,960,000,000, missing estimates of $7,051,017,984 by $-91,017,984.Stock price change since market close: -3.24%You can see Quiver Quantitative's $GILD stock page to ...

Gilead Sciences, Inc. (NASDAQ:GILD) earned $2.03 per share on an adjusted basis, $0.12 above the average estimate compiled by LSEG.

To see the full list of analyst ... the GILD Stock Forecast page. ... According to Spark, TipRanks’ AI Analyst, GILD is a Outperform. Score is driven primarily by strong financial performance (high margins, solid free cash flow, and improved leverage) and a positive earnings update with ...